



ESC CARDIOVASCULAR ROUND TABLE

WORKSHOP ON REGULATORY ASPECTS OF ATRIAL FIBRILLATION

15 – 16 September 2009, HILTON PADDINGTON Hotel - London

PROGRAMME DAY 1

Tuesday 15 September 2009 – Chairpersons: N Danchin (TBC) - S Longman

14:00 – 14:10	Welcome and introduction	John Camm, UK
<u>14:10 – 14:55</u>	BACKGROUND – ATRIAL FLUTTER and FIBRILLATION	
14:10 – 14:20	Epidemiology of atrial fibrillation and flutter (atrial Fib/Fl)	Paulus Kirchhof, D
14:20 – 14:30	Current treatment strategies for atrial Fib/Fl	John Camm, UK
14:30 – 14:40	Unmet medical need for patients with atrial Fib/Fl	Anil-Martin Sinha, DE
14:40 – 14:55	<i>Questions/Discussion</i>	All
<u>14:55 – 15:10</u>	<u>TOPIC 1:</u>	
14:55 – 15:05	Pharmacological cardioversion – what constitutes cardioversion (and recurrence)?	Juan Tamargo Menendez, ES
15:05 – 15:15	Maintenance of sinus rhythm – is it possible?	Etienne Aliot, FR
15:15 – 15:25	Rate control – how should it be measured?	Irene Savelieva, UK
15:25 – 15:35	Critique of rate versus rhythm control trials	John Camm, UK
15:35 – 16:05	<i>Questions/Discussion</i>	All
16:05 – 16:35	COFFEE BREAK	
<u>16:35 – 18:00</u>	<u>TOPIC 2:</u>	
16:35 – 16:45	Should atrial fibrillation and atrial flutter be distinguished?	Etienne Aliot, FR
16:45 – 16:55	Does the temporal pattern of atrial Fib/Fl (paroxysmal versus persistent) matter?	John Camm, UK
16:55 – 17:05	Is the underlying aetiology of atrial Fib/Fl important?	Juan Tamargo Menendez, ES
17:05 – 17:15	How can symptoms and quality of life be assessed?	Anil-Martin Sinha, DE
17:15 – 17:25	Which ancillary studies are important: LV function, electrophysiological testing, and defibrillation threshold?	
17:25 – 17:35	In which settings is an active comparator study feasible?	Pieter de Graeff, NL
17:35 – 17:45	Relevant clinical endpoints and their implications for indication(s)	Pieter de Graeff, NL
17:45 – 18:00	<i>Questions/Discussion</i>	All
18:00	<i>End of the day</i>	
20:00	DINNER	

WORKSHOP ON REGULATORY ASPECTS OF ATRIAL FIBRILLATION

15 – 16 September 2009, HILTON PADDINGTON Hotel - London

PROGRAMME DAY 2

Wednesday 16 September 2009 – Chairpersons: J Camm – N Jackson		
9:00 – 10:30	BREAKOUT SESSIONS	
	SESSION ① Chair: Pieter de Graeff Is a large scale major cardiovascular outcomes trial always necessary for the approval of drugs designed to control rate or manage rhythm?	SESSION ② Chair: Paulus Kirchhof ECG endpoints for atrial fibrillation trials
10:30 – 11:00	Reporting back from sessions and discussions	All
11:00 – 11:15	COFFEE BREAK	
11:15 – 11:45	Formulation of consensus points	Paulus Kirchhof, D
11:45 – 12:00	Next steps and closure	John Camm, UK
12:00	END OF THE WORKSHOP AND LUNCH	